{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:30:24Z","timestamp":1794637824499,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01260-6","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T21:00:15Z","timestamp":1743800415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-8616","authenticated-orcid":false,"given":"Federico","family":"Lussana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-2159","authenticated-orcid":false,"given":"Chiara F.","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-5123","authenticated-orcid":false,"given":"Giuseppe","family":"Gritti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gaipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Cabiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5345-7448","authenticated-orcid":false,"given":"Chiara","family":"Buracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Borleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Rizzuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Paganessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Meli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tettamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Risca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Spinozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Benedicenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Capelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Introna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Golay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Montini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Dastoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-6173","authenticated-orcid":false,"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"1260_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl J Med. 2018;378:439\u201348.","journal-title":"N. Engl J Med"},{"key":"1260_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, et al. Optimizing chimeric antigen receptor t-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020;38:415\u201322.","journal-title":"J Clin Oncol"},{"key":"1260_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491\u2013502.","journal-title":"Lancet"},{"key":"1260_CR4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-Cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330.","journal-title":"N Engl J Med"},{"key":"1260_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1260_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.","journal-title":"Mol Ther Oncolytics"},{"key":"1260_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/MOH.0000000000000178","volume":"22","author":"CF Magnani","year":"2015","unstructured":"Magnani CF, Biondi A, Biagi E. Donor-derived CD19-targeted T cells in allogeneic transplants. Curr Opin Hematol. 2015;22:497\u2013502.","journal-title":"Curr Opin Hematol"},{"key":"1260_CR8","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1089\/hum.2017.207","volume":"29","author":"CF Magnani","year":"2018","unstructured":"Magnani CF, Mezzanotte C, Cappuzzello C, Bardini M, Tettamanti S, Fazio G, et al. Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with sleeping beauty transposon for the treatment of acute lymphoblastic leukemia. Hum Gene Ther. 2018;29:602\u201313.","journal-title":"Hum Gene Ther"},{"key":"1260_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jaut.2017.08.003","volume":"85","author":"A Biondi","year":"2017","unstructured":"Biondi A, Magnani CF, Tettamanti S, Gaipa G, Biagi E. Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia. J Autoimmun. 2017;85:141\u201352.","journal-title":"J Autoimmun"},{"key":"1260_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0092-8674(00)80436-5","volume":"91","author":"Z Ivics","year":"1997","unstructured":"Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91:501\u201310.","journal-title":"Cell"},{"key":"1260_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867013","volume":"13","author":"A Moretti","year":"2022","unstructured":"Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The past, present, and future of non-viral CAR T Cells. Front Immunol. 2022;13:867013.","journal-title":"Front Immunol"},{"key":"1260_CR12","doi-asserted-by":"crossref","unstructured":"Magnani CF, Tettamanti S, Alberti G, Pisani I, Biondi A, Serafini M, et al. Transposon-Based CAR T cells in acute leukemias: where are we going? Cells;9. 2020.","DOI":"10.3390\/cells9061337"},{"key":"1260_CR13","doi-asserted-by":"crossref","unstructured":"Introna M, Lussana F, Algarotti A, Gotti E, Valgarsdottir R, Mico C, et al. Phase II Study Of Sequential Infusion of DLI and cytokine induced killer cells for patients relapsed after alloHSCT. Biol Blood Marrow Transplant. 2017;23:2070\u20138.","DOI":"10.1016\/j.bbmt.2017.07.005"},{"key":"1260_CR14","doi-asserted-by":"crossref","unstructured":"Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, et al. Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Investig. 2020;130:6021\u201333.","DOI":"10.1172\/JCI138473"},{"key":"1260_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"1260_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233151","volume":"341","author":"A Aiuti","year":"2013","unstructured":"Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341:1233151.","journal-title":"Science"},{"key":"1260_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0022-2836(02)00991-9","volume":"323","author":"TJ Vigdal","year":"2002","unstructured":"Vigdal TJ, Kaufman CD, Izsvak Z, Voytas DF, Ivics Z. Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1\/mariner transposable elements. J Mol Biol. 2002;323:441\u201352.","journal-title":"J Mol Biol"},{"key":"1260_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/mt.2016.11","volume":"24","author":"A Gogol-D\u00f6ring","year":"2016","unstructured":"Gogol-D\u00f6ring A, Ammar I, Gupta S, Bunse M, Miskey C, Chen W, et al. Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T cells. Mol Ther. 2016;24:592\u2013606.","journal-title":"Mol Ther"},{"key":"1260_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJMp2211729","volume":"388","author":"KN Vokinger","year":"2023","unstructured":"Vokinger KN, Avorn J, Kesselheim AS. Sources of innovation in gene therapies - approaches to achieving affordable prices. N. Engl J Med. 2023;388:292\u20135.","journal-title":"N. Engl J Med"},{"key":"1260_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl J Med. 2018;378:449\u201359.","journal-title":"N. Engl J Med"},{"key":"1260_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood-2021-153955","volume":"138","author":"NV Frey","year":"2021","unstructured":"Frey NV, Gill S, Hwang W-T, Luger SM, Martin ME, McCurdy SR, et al. CART22-65s co-administered with huCART19 in adult patients with relapsed or refractory ALL. Blood. 2021;138:469.","journal-title":"Blood"},{"key":"1260_CR22","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-Cell acute lymphoblastic leukemia. J Clin Oncol. 2021;39:3352\u201363.","journal-title":"J Clin Oncol"},{"key":"1260_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/hematology.2024000534","volume":"2024","author":"MR Bishop","year":"2024","unstructured":"Bishop MR. Late complications and long-term care of adult CAR T-cell patients. Hematology. 2024;2024:109\u201315.","journal-title":"Hematology"},{"key":"1260_CR24","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","volume":"112","author":"R Nishimura","year":"2008","unstructured":"Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112:2563\u201374.","journal-title":"Blood"},{"key":"1260_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm.4258","volume":"23","author":"A Ghosh","year":"2017","unstructured":"Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017;23:242\u20139.","journal-title":"Nat Med"},{"key":"1260_CR26","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl J Med. 2023;388:1284\u201395.","journal-title":"N. Engl J Med"},{"key":"1260_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00881-z","volume":"13","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Khaled SK, Wang Y, Wang X, Palmer J, Clark MC, et al. Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed\/refractory acute lymphoblastic leukemia. Blood Cancer J. 2023;13:107.","journal-title":"Blood Cancer J"},{"key":"1260_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1089\/hum.2023.128","volume":"34","author":"C Bonini","year":"2023","unstructured":"Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani C, Qasim W. Genome editing in engineered T cells for cancer immunotherapy. Hum Gene Ther. 2023;34:853\u201369.","journal-title":"Hum Gene Ther"},{"key":"1260_CR29","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022;9:e833\u2013e43.","journal-title":"Lancet Haematol"},{"key":"1260_CR30","doi-asserted-by":"publisher","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","volume":"14","author":"G Ottaviano","year":"2022","unstructured":"Ottaviano G, Georgiadis C, Gkazi SA, Syed F, Zhan H, Etuk A, et al. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci Transl Med. 2022;14:eabq3010.","journal-title":"Sci Transl Med"},{"key":"1260_CR31","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54:1643\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"1260_CR32","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023;41:1664\u20139.","journal-title":"J Clin Oncol"},{"key":"1260_CR33","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1200\/JCO.21.01405","volume":"40","author":"RM Myers","year":"2022","unstructured":"Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol. 2022;40:932\u201344.","journal-title":"J Clin Oncol"},{"key":"1260_CR34","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.bulcan.2021.08.001","volume":"108","author":"ME Dourthe","year":"2021","unstructured":"Dourthe ME, Baruchel A. CAR T-cells in acute lymphoblastic leukemia: current results. Bull Cancer. 2021;108:S40\u2013S54.","journal-title":"Bull Cancer"},{"key":"1260_CR35","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","volume":"4","author":"MC Pasquini","year":"2020","unstructured":"Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414\u201324.","journal-title":"Blood Adv"},{"key":"1260_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007118","volume":"11","author":"BD Shah","year":"2023","unstructured":"Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, et al. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother cancer. 2023;11:e007118.","journal-title":"J Immunother cancer"},{"key":"1260_CR37","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/bloodadvances.2020003482","volume":"6","author":"P Grover","year":"2022","unstructured":"Grover P, Veilleux O, Tian L, Sun R, Previtera M, Curran E, et al. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2022;6:1608\u201318.","journal-title":"Blood Adv"},{"key":"1260_CR38","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133:1652\u201363.","journal-title":"Blood"},{"key":"1260_CR39","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1126\/science.1121411","volume":"311","author":"SH Thorne","year":"2006","unstructured":"Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311:1780\u20134.","journal-title":"Science"},{"key":"1260_CR40","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.22.01214","volume":"41","author":"T Wang","year":"2022","unstructured":"Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, et al. Coadministration of CD19- and CD22-Directed Chimeric Antigen receptor T-Cell therapy in childhood B-Cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II Trial. J Clin Oncol. 2022;41:1670\u201383.","journal-title":"J Clin Oncol"},{"key":"1260_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003293","volume":"135","author":"J Pan","year":"2020","unstructured":"Pan J, Zuo S, Deng B, Xu X, Li C, Zheng Q, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL. Blood. 2020;135:387\u201391.","journal-title":"Blood"},{"key":"1260_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","volume":"37","author":"V Ceolin","year":"2023","unstructured":"Ceolin V, Brivio E, van Tinteren H, Rheingold SR, Leahy A, Vormoor B, et al. Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia. Leukemia. 2023;37:53\u201360.","journal-title":"Leukemia"},{"key":"1260_CR43","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/bjh.14899","volume":"182","author":"N Turazzi","year":"2018","unstructured":"Turazzi N, Fazio G, Rossi V, Rolink A, Cazzaniga G, Biondi A, et al. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018;182:939\u201343.","journal-title":"Br J Haematol"},{"key":"1260_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","volume":"30","author":"CF Magnani","year":"2023","unstructured":"Magnani CF, Myburgh R, Brunn S, Chambovey M, Ponzo M, Volta L, et al. Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Mol Ther Oncolytics. 2023;30:56\u201371.","journal-title":"Mol Ther Oncolytics"},{"key":"1260_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ymthe.2003.11.009","volume":"9","author":"Z Izsvak","year":"2004","unstructured":"Izsvak Z, Ivics Z. Sleeping beauty transposition: biology and applications for molecular therapy. Mol Ther. 2004;9:147\u201356.","journal-title":"Mol Ther"},{"key":"1260_CR46","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","volume":"130","author":"KT Mueller","year":"2017","unstructured":"Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, et al. Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. 2017;130:2317\u201325.","journal-title":"Blood"},{"key":"1260_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"1260_CR48","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","volume":"12","author":"MA Pule","year":"2005","unstructured":"Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933\u201341.","journal-title":"Mol Ther"},{"key":"1260_CR49","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/mt.2013.192","volume":"21","author":"AA Hombach","year":"2013","unstructured":"Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation. Mol Ther. 2013;21:2268\u201377.","journal-title":"Mol Ther"},{"key":"1260_CR50","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138:1391\u2013405.","journal-title":"Blood"},{"key":"1260_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00609-1","volume":"8","author":"D Cesana","year":"2017","unstructured":"Cesana D, Santoni de Sio FR, Rudilosso L, Gallina P, Calabria A, Beretta S, et al. HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells. Nat Commun. 2017;8:498.","journal-title":"Nat Commun"},{"key":"1260_CR52","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.2019.37.15_suppl.2510","volume":"37","author":"NN Shah","year":"2019","unstructured":"Shah NN, Zhu F, Schneider D, Taylor C, Krueger W, Worden A, et al. Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. JCO. 2019;37:2510.","journal-title":"JCO"},{"key":"1260_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307\u201312.","journal-title":"Nature"},{"key":"1260_CR54","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI130144","volume":"130","author":"CL Nobles","year":"2020","unstructured":"Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Investig. 2020;130:673\u201385.","journal-title":"J Clin Investig"},{"key":"1260_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30:338\u201341.","journal-title":"Nat Med"},{"key":"1260_CR56","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"Elsallab","year":"2024","unstructured":"Elsallab, Ellithi M, Lunning MA M, D\u2019Angelo, Ma C, Perales MA J, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood. 2024;143:2099\u2013105.","journal-title":"Blood"},{"key":"1260_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602:503\u20139.","journal-title":"Nature"},{"key":"1260_CR58","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","volume":"7","author":"R Bassan","year":"2023","unstructured":"Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, et al. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv. 2023;7:4448\u201361.","journal-title":"Blood Adv"},{"key":"1260_CR59","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2020007311","volume":"137","author":"JM Ribera","year":"2021","unstructured":"Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesc\u00e0 E, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021;137:1879\u201394.","journal-title":"Blood"},{"key":"1260_CR60","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143:1891\u2013902.","journal-title":"Blood"},{"key":"1260_CR61","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","volume":"391","author":"MR Litzow","year":"2024","unstructured":"Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N. Engl J Med. 2024;391:320\u201333.","journal-title":"N. Engl J Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01260-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T06:09:15Z","timestamp":1743833355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1260"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01260-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}